BAT Releases 2024 Fiscal Year Trading Update on December 11th

Dec.11.2024
BAT Releases 2024 Fiscal Year Trading Update on December 11th
BAT announces strong growth in new product categories and traditional tobacco revenues for the second half of 2024 fiscal year.

On December 11, British American Tobacco (BAT) released a trading update for the fiscal year ending 2024. The company stated that the accelerated growth in the second half of 2024 was in line with expectations, primarily driven by innovation in new product categories. Revenue from new product categories and traditional tobacco is expected to increase in the second half of the year compared to the first half.


BAT expects that by the end of 2024, the cash conversion rate will exceed 90%, while the leverage ratio will be within the target range of 2.0-2.5 times. Additionally, they have expressed support for the Canadian Companies' Creditors Arrangement Act (CCAA) and are hopeful to reach a conclusion that is beneficial for all stakeholders.


In the traditional tobacco industry, the United States' business actions continued to gain momentum in the second half of the year; in the AME and APMEA regions, its market share continued to grow. Investments in the first half of the year in the US business actions and wholesale inventory adjustments drove an increase in organic sales volume and financial performance in the traditional tobacco business in the second half of the year. Despite a slight decrease in value share due to the impact of the US market's geographic mix, volume share increased by 20 basis points in key markets.


The performance of new business categories is also improving. Vuse e-cigarettes maintain a leading market share globally, with a 40.3% share in key markets (50.7% share in tracked channels in the U.S.). Meanwhile, the innovative product line of the glo brand is showing signs of accelerated growth in the second half of the year, with new products like glo Hyper Pro driving sales growth. The Velo brand continues to experience strong growth in markets outside the U.S., solidifying its position as a leader in the oral market.


BAT expects a decrease in sales of approximately 2% in 2024, with organic revenue and profit growth forecasted to be in the low single digits. Planned capital expenditure is around 600 million pounds, and net financial expenses are expected to be 1.6 billion pounds, impacted by fluctuations in exchange rates and interest rates.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. Health Secretary Criticizes Slow FDA Action, Vows to Crack Down on Illegal Vapes
U.S. Health Secretary Criticizes Slow FDA Action, Vows to Crack Down on Illegal Vapes
U.S. Health Secretary Robert Kennedy Jr. on Wednesday criticized the FDA for slow approval of U.S.-made e-cigarettes, saying the delay has allowed Chinese products to dominate the market and target American youth. He told lawmakers he would move to remove illegal Chinese vapes.
May.16 by 2FIRSTS.ai
U.S. Texas Governor Signs E-Cigarette Bill: Bans Vapes Made by China and "Foreign Adversaries"
U.S. Texas Governor Signs E-Cigarette Bill: Bans Vapes Made by China and "Foreign Adversaries"
Texas Governor Greg Abbott signed SB 2024, effective September 1, 2025, tightening e-cigarette regulations. The law targets marketing to minors, vape products disguised as everyday items, illegal additives, and e-cigarettes made by "foreign adversaries" like China.
Jun.24 by 2FIRSTS.ai
FDA Appoints Bret Koplow as Acting Director of CTP
FDA Appoints Bret Koplow as Acting Director of CTP
According to the U.S. Food and Drug Administration’s website, Bret Koplow has been appointed acting director of the Center for Tobacco Products (CTP). Koplow has been with the FDA since 2011, holding several key roles, most recently serving as senior advisor to the FDA Commissioner.
May.21 by 2FIRSTS.ai
Brazil’s Health Surveillance Agency Wins World No Tobacco Day Award for E-Cigarette Ban Recognized by WHO
Brazil’s Health Surveillance Agency Wins World No Tobacco Day Award for E-Cigarette Ban Recognized by WHO
Brazil’s National Health Surveillance Agency (Anvisa) has been awarded the World No Tobacco Day Award by the World Health Organization for its outstanding efforts in tobacco control and enforcing the e-cigarette ban. The award ceremony was held at the Pan American Health Organization headquarters in Brasília.
May.30 by 2FIRSTS.ai
Ispire Reports FY2025 Q3 Revenue Down 12.7% to $26.2M; Secures Temporary Nicotine Production License in Malaysia
Ispire Reports FY2025 Q3 Revenue Down 12.7% to $26.2M; Secures Temporary Nicotine Production License in Malaysia
Ispire’s FY2025 Q3 revenue fell 12.7% to $26.2 million, with net loss widening to $10.9 million. The company is shifting manufacturing to Malaysia, aiming to cut costs by $8 million annually, and has obtained a temporary nicotine production license. It also filed a blockchain-based PMTA component with the FDA and launched the Sprout™ cannabis device with Raw Garden to grow its presence in emerging markets.
May.13 by 2FIRSTS.ai
Five Key Takeaways from the E-Cigarette Regulatory Press Conference: Stricter Oversight, Production Control, and Crackdown on Grey Market — In-Depth Analysis by 2Firsts’ Alan Zhao on Policy Logic and Industry Impact
Five Key Takeaways from the E-Cigarette Regulatory Press Conference: Stricter Oversight, Production Control, and Crackdown on Grey Market — In-Depth Analysis by 2Firsts’ Alan Zhao on Policy Logic and Industry Impact
Ahead of World No Tobacco Day, China’s tobacco regulator signaled a push for stricter e-cigarette oversight at a press conference. 2Firsts CEO Alan Zhao noted that regulation is entering a deeper phase, with new focus on export re-entry, international pressure, and the inclusion of herbal vapor products. Authorities also vowed to crack down on illegal operations and unapproved projects.
May.30 by 2FIRSTS.ai